Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Positive Data Give DePuy Synthes' Attune Further Knee-Up

Executive Summary

Results of a study by the Canadian Radiostereometric Analysis Network show that the tibial base of DePuy Synthes' Attune knee replacement achieves stable fixation out to two years and recently announced results from the UK's National Joint Registry show a 98.1% four-year implant survivorship rate with Attune in a "real-world" setting.

You may also be interested in...



Earnings Winners & Losers: Orthopedics Firms, JNJ, NUVA, SNN, SYK, ZBH

With earnings reporting season now in full swing, Medtech Insight highlights which companies have exceeded expectations and which ones continue to see their bottom-line sink. This edition throws the spotlight on some of the notable players in the orthopedics space.

Minute Insight: Titan Medical Cuts Costs As It Continues ‘Strategic Review’

The Canadian robotic surgery company is still working toward an FDA approval for its Enos single-access robotic surgery system, but is laying off 40 people in its Chapel Hill, NC, offices to save money.

Cleerly Advances CCTA Digital Pathway To Stop Heart Disease

Using artificial intelligence and coronary computed tomography angiography Cleerly is trying to shift cardiology's focus from symptoms-based interventions to prevention and treatment of the underlying vascular disease.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT105030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel